TGIF2LX1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the TGIF2LX1 protein, which is a member of the TGIF (thymine-rich, G-rich, and immunoglobulin-like factors) family. This protein plays a significant role in regulating gene expression and cellular development, particularly in the context of embryonic development and patterning. TGIF2LX1 acts as a transcriptional co-repressor, modulating the activity of various transcription factors by binding to their target genes. Inhibition of TGIF2LX1 is achieved primarily by binding to its critical regions, such as the DNA-binding domain or interaction sites essential for recruiting other proteins involved in transcriptional regulation. By occupying these binding sites, TGIF2LX1 inhibitors effectively disrupt the protein's normal regulatory functions, leading to altered gene expression profiles. Some inhibitors may also function through allosteric mechanisms, binding to regions separate from the active site and inducing conformational changes that diminish the protein's activity. The binding interactions between these inhibitors and TGIF2LX1 are typically stabilized by a range of non-covalent forces, including hydrogen bonds, hydrophobic interactions, van der Waals forces, and ionic interactions.
Structurally, TGIF2LX1 inhibitors demonstrate considerable diversity, enabling specific interactions with different regions of the TGIF2LX1 protein. These inhibitors often incorporate functional groups such as hydroxyl, carboxyl, or amine groups, facilitating strong interactions through hydrogen bonding and ionic interactions with key amino acid residues in the protein's binding pockets. Many TGIF2LX1 inhibitors also feature aromatic rings or heterocyclic structures that enhance hydrophobic interactions with non-polar regions of the protein, thereby contributing to the overall stability of the inhibitor-protein complex. The physicochemical properties of TGIF2LX1 inhibitors, including molecular weight, solubility, lipophilicity, and polarity, are meticulously optimized to ensure effective binding and stability in various biological environments. This balance between hydrophilic and hydrophobic regions allows TGIF2LX1 inhibitors to interact selectively with both polar and non-polar areas of the protein, ensuring robust and efficient inhibition of TGIF2LX1 activity across diverse cellular contexts.
VOIR ÉGALEMENT...
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
En tant qu'inhibiteur de la kinase du récepteur TGF-β, le LY364947 pourrait réduire l'expression de TGIF2LX en empêchant l'activation de sa cascade de signalisation. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
Cet inhibiteur sélectif du récepteur I du TGF-β peut potentiellement supprimer l'expression de TGIF2LX en inhibant l'activation transcriptionnelle médiée par le TGF-β. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
RepSox est un inhibiteur sélectif du récepteur TGF-β qui pourrait diminuer l'expression de TGIF2LX en atténuant la signalisation TGF-β. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $100.00 $408.00 | 6 | |
Cette petite molécule peut indirectement diminuer l'expression de TGIF2LX en modulant les réponses fibrogéniques médiées par le TGF-β. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1740.00 | ||
L'halofuginone inhibe la signalisation du TGF-β, ce qui pourrait entraîner une réduction de l'expression de TGIF2LX en perturbant la régulation des gènes en aval. | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $30.00 $101.00 $277.00 $959.00 | 2 | |
Le trilast peut inhiber l'expression de TGIF2LX en antagonisant le TGF-β et en réduisant l'activité transcriptionnelle qui lui est associée. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $86.00 | 3 | |
En tant qu'inhibiteur de la kinase du récepteur I du TGF-β, le SD-208 pourrait réduire l'expression de TGIF2LX en bloquant la voie de signalisation du TGF-β. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197 inhibe la signalisation TGF-β, ce qui pourrait entraîner une diminution de l'expression de TGIF2LX en interférant avec ses mécanismes d'induction. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $87.00 $270.00 | 9 | |
Ce produit chimique peut réduire l'expression de TGIF2LX en inhibant l'activité kinase du récepteur I du TGF-β, bloquant ainsi sa voie de signalisation. | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | $573.00 | ||
Le vactosertib, en inhibant le récepteur I du TGF-β, pourrait potentiellement diminuer l'expression de TGIF2LX par la suppression de sa voie de signalisation. | ||||||